Search
Back 

NRG-GU001

NRG-GU001: Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer

 

NRG-GU001 PowerPoint Presentation

Letter to Potential Site Investigators

Principal Investigator

Libni Eapen, MD, FRCPC

Primary Objective

To evaluate the ability of post-cystectomy adjuvant radiotherapy to  reduce pelvic tumor recurrence 

Patient Population

Patients with pT3 / pT4 pN0-2 urothelial ( pure urothelial or primary urothelial mixed with other subtypes) bladder cancer following radical cystectomy with ileal conduit

Target Accrual

185 patients

Status

Activation: January 2, 2015

Closure/Termination: February 1, 2017

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website

Copyright 2017 by NRG Oncology